A new analysis of the ROMEO study data, published in Clinical Ophthalmology, revealed that the Omni Surgical System (Sight Sciences) was as effective in lowering intraocular pressure (IOP) and reducing medication usage in advanced glaucoma as in mild and moderate stages. The study was conducted by Sight Sciences, Inc.
The analysis evaluated 129 patients with primary open-angle glaucoma, categorized by severity: mild (79 eyes), moderate (42 eyes), and advanced (6 eyes). The Omni procedure, which addresses outflow resistance in glaucomatous eyes, resulted in significant IOP reductions across all groups, with most eyes achieving IOP levels of 18 mmHg or less by month 12.
Key findings included:
- Significant IOP reductions in 70% of eyes.
- Consistent IOP reduction percentages across all severity groups.
- Mean IOP at 12 months ranged between 14 mmHg and 16 mmHg.
- Medication reductions in 50% to 69% of patients.
The study suggests that Omni is effective regardless of glaucoma severity, challenging previous beliefs about the limitations of minimally invasive glaucoma surgery (MIGS) in advanced cases. Dr. Jaime E. Dickerson, Jr. of Sight Sciences highlighted the study's implications for treating advanced glaucoma.
"Clinical trials and real-world results continue to demonstrate favorable Omni treatment outcomes across different stages of glaucoma," said Paul Badawi, cofounder and CEO of Sight Sciences. "These findings reinforce our dedication to offering effective treatment options for glaucoma patients at every stage of the disease and also fuel our initiatives to continue reimagining eye care with transformative technology and an interventional mindset."
